Registry for patients with IgA Nephropathy
Construction of a Multi-center Database for Primary IgA Nephropathy
This study is creating a registry for people with IgA nephropathy in China to help improve diagnosis and treatment by collecting and organizing important health information.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Sex | All |
| Sponsor | Ruijin Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT04858724 on ClinicalTrials.gov |
What this trial studies
This study aims to establish a comprehensive registry for patients diagnosed with primary IgA nephropathy (IgAN) in China. It will create a structured dataset and standardized data collection templates to improve the quality of clinical diagnosis and treatment. By integrating multi-center data and establishing a biobank, the study seeks to enhance research capabilities and facilitate better understanding of IgAN. The initiative addresses the challenges of clinical heterogeneity and the lack of biomarkers, ultimately aiming to improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals of any age or gender with a kidney biopsy-confirmed diagnosis of primary IgA nephropathy.
Not a fit: Patients with secondary IgA nephropathy due to systemic diseases or those who refuse to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could lead to improved diagnosis, treatment, and management of IgA nephropathy, potentially reducing the progression to end-stage renal failure.
How similar studies have performed: While there have been various studies on IgAN, this approach of creating a standardized multi-center registry is relatively novel and aims to address significant gaps in current research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. No age limit, no gender limit; 2. Kidney biopsy confirmed primary IgA nephropathy; 3. Sign the informed consent form voluntarily Exclusion Criteria: 1. IgA nephropathy is secondary to systemic diseases such as systemic lupus erythematosus and allergic purpura; 2. IgAN is clinically diagnosed but not confirmed by pathology; 3. The patient refuses to participate; 4. Patients judged by other investigators to be unsuitable for inclusion in the study.
Where this trial is running
Shanghai, Shanghai Municipality
- Ruijin Hospital, Shanghai JiaoTong University School of Medicine — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Principal investigator: Jingyuan Xie — Ruijin Hospital
- Study coordinator: Jingyuan Xie
- Email: nephroxie@163.com
- Phone: 13761056656
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.